Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 277Lenalidomide 155Bortezomib 152Cyclophosphamide 115Melphalan 107Calcium Dobesilate 107fludarabine phosphate 70carfilzomib 61pomalidomide 55Peripheral Blood Stem Cell Transplantation 53Whole-Body Irradiation 52Mycophenolic Acid 52Granulocyte Colony-Stimulating Factor 52Filgrastim 52daratumumab 46fludarabine 43Tacrolimus 41ixazomib 40Busulfan 40Thalidomide 36Cyclosporine 32dexamethasone acetate 26Stem Cell Transplantation 26Antilymphocyte Serum 25dexamethasone 21-phosphate 22plerixafor 20auricularum 20belantamab mafodotin 19Prednisone 19Etoposide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Multiple Myeloma × Hematopoietic Stem Cell Mobilization × Clear all
NCT02441686 2026-01-13

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
46 enrolled 13 charts
Plasma cell

Multiple Myeloma

NCT02375555 2024-10-01

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

Dana-Farber Cancer Institute

Phase 2 Completed
40 enrolled 18 charts
Plasma cell

Multiple Myeloma

NCT01731886 2020-02-05

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

Columbia University

Phase 4 Completed
60 enrolled 14 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡